Anti-IL-12β (Ustekinumab), Human IgG1 Antibody | A2137

The research-grade biosimilar is a human IgG1? monoclonal antibody that was generated using human immunoglobulin (hu-Ig) transgenic mice. This monoclonal antibody specifically binds to the p40 subunit of IL-12 and IL-23, thus preventing their association with the IL-12R?1 receptor expressed on the NK cell and T cell surface and resulting in reduced IL-12 and IL-23 mediated signaling, activation, and cytokine production. The original monoclonal antibody was developed by Centocor and received FDA approval in 2009 for use in the treatment of psoriasis. Recently, it has been approved for the treatment of Crohn’s disease and ulcerative colitis.

A2137 | Anti-IL-12? (Ustekinumab), Human IgG1 Antibody DataSheet

Antibody Target: IL-12?

Target Alternative Name: IL-12?, IL12?, IL 12?

Tag Line: A human monoclonal antibody that targets IL-12 and IL-23 by inhibiting their interaction with the receptor IL-12R?1 and thus disrupting IL-12 and IL-23 mediated signaling that is central to inflammatory diseases

Category: Biosimilars

Host: Recombinant

Isotype: IgG1, kappa

Species Reactivities: Human

Immunogen Sequence: Ustekinumab

Accession #: DB05679

Gene ID:

Appearance: Colorless liquid

Form: Liquid

Concentration: Lot specific

Formulation: In PBS pH 7.5

Purification: Protein A purified

Application: In vitro studies

Positive Control:

Application And Usages: In vitro studies

Country of Animal Origin: USA

Country of Manufacture: USA

Usage: For Research Use Only! Not to be used in humans.

Handling: The antibody solution should be gently mixed before use.

Western Blot Verified: FALSE

Immunocytochemistry Verified: FALSE

Immunofluorescence Verified: FALSE

Immunoprecipitation Verified: FALSE

FACS Verified: FALSE

ELISA Verified: FALSE

ChIP Verified: FALSE

Dot Blot Verified: FALSE

Flow Cytometry Verified: FALSE